ZS Pharma submits New Drug Application to FDA for ZS-9 for treatment of hyperkalemia
ZS Pharma announced it has submitted a NDA to the FDA for ZS-9 (sodium zirconium cyclosilicate). The NDA requests FDA approval of ZS-9 for the treatment of hyperkalemia. ZS-9 is an insoluble, non-absorbed zirconium silicate designed and engineered to preferentially trap potassium ions. May 26, 2015